Go Deep
NATCO Pharma Limited
NATCO Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,298 | 13.0 | 1.64 | 0.08 | 823.65 |
| Oct 2026 | 23,811 | 12.5 | 1.57 | 0.08 | 789.40 |
NATCO Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 7,352,000,000.0 | 7,391,000,000.0 | 6,473,000,000.0 | 13,630,000,000.0 |
| Net Profit | 2,065,000,000.0 | 2,679,000,000.0 | 1,515,000,000.0 | 5,184,000,000.0 |
| EPS | 11.5 | 15.0 | 8.5 | 28.9 |
NATCO Pharma Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 40,445,000,000.0 | 44,116,000,000.0 | 39,788,000,000.0 | 26,969,000,000.0 | — |
| Net Profit | 14,185,000,000.0 | 18,854,000,000.0 | 13,883,000,000.0 | 7,153,000,000.0 | — |
| EPS | 79.2 | 105.3 | 77.3 | 39.2 | — |
NATCO Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 110,737,000,000.0 | 86,308,000,000.0 | 69,063,000,000.0 | 56,574,000,000.0 | — |
| Total Liabilities | 18,526,000,000.0 | 10,185,000,000.0 | 10,532,000,000.0 | 7,836,000,000.0 | — |
| Total Equity | 92,211,000,000.0 | 76,070,000,000.0 | 58,531,000,000.0 | 48,738,000,000.0 | — |
Owes vs Owns
NATCO Pharma Limited owed ₹0.17 for every ₹1 it owned in Mar 2026, up from ₹0.14 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.12× | 0.15× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
NATCO Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 25.2%Receivables 8.0%Inventory 8.2%Fixed assets (tangible) 26.3%Intangible assets 2.3%Long-term investments 20.6%Other assets 9.5%
How it's funded — Mar 2026
Short-term debt 5.5%Long-term debt 0.9%Payables 3.7%Other liabilities 6.7%Shareholders' equity 83.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,788.1 | 2,807.6 | 1,776.0 | 1,124.8 |
| Receivables | 881.2 | 1,246.6 | 1,188.9 | 856.1 |
| Inventory | 908.5 | 765.8 | 700.5 | 742.9 |
| Fixed assets (tangible) | 2,908.8 | 2,706.1 | 2,504.0 | 2,330.3 |
| Intangible assets | 257.2 | 266.1 | 193.1 | 187.8 |
| Long-term investments | 2,275.7 | 0.0 | 95.9 | 87.3 |
| Other assets | 1,054.2 | 838.6 | 447.9 | 328.2 |
| Liabilities & equity | ||||
| Short-term debt | 606.4 | 273.1 | 363.2 | 174.4 |
| Long-term debt | 100.0 | 0.0 | 5.3 | 1.1 |
| Payables | 409.3 | 274.9 | 235.5 | 263.8 |
| Other liabilities | 736.9 | 470.5 | 449.2 | 344.3 |
| Shareholders' equity | 9,221.1 | 7,612.3 | 5,853.1 | 4,873.8 |
| Net tangible assets | 8,963.9 | 7,340.9 | 5,660.0 | 4,686.0 |
NATCO Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 17,683,000,000.0 | 16,968,000,000.0 | 12,116,000,000.0 | 8,491,000,000.0 | — |
| Investing Activities | -20,817,000,000.0 | -14,145,000,000.0 | -10,327,000,000.0 | -4,771,000,000.0 | — |
| Financing Activities | 2,975,000,000.0 | -2,107,000,000.0 | -2,469,000,000.0 | -3,630,000,000.0 | — |